Thursday, Sept 25, 2025 | 2 minutes and 18 seconds or ~138 heartbeats  

ARPA-H Launches Two Groundbreaking Programs 

What’s happening: Today, ARPA-H announced two new programs that revolutionize genetic medicine development and manufacturing.

Enabling precision medicines to THRIVE. The THRIVE program, or Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines, aims to develop integrated platform technologies to accelerate precision genetic medicines and provide single-intervention precision treatments to slow, reverse, or prevent diseases at the genetic level. 

Why it’s needed: Chronic genetic conditions often progress rapidly, cause severe disability, and result in poor quality or significant loss of life. Most urgent are rare diseases, which collectively affect over 30 million Americans, mostly newborns, infants, and children. Despite their high unmet needs, roughly 95% of rare diseases have no approved treatments.

• “By transforming precision genetic medicines into universal, widely available cures, THRIVE exemplifies the unique health care approach needed to slow, reverse, or prevent genetic diseases for all Americans, solidifying the U.S. as the leader in realizing advanced medical treatments,” said ARPA-H Acting Director Jason Roos, Ph.D.

From the Program Manager: "At ARPA-H, our vision is to empower every individual not just to survive, but to thrive. By developing pioneering interventions to halt, reverse, or prevent chronic diseases at the genetic level we aim to transform the possibilities for better health outcomes and improved life expectancies,” said THRIVE Program Manager Mimi Lee, M.D., Ph.D.  “THRIVE is designed for these precision genetic medicines to be distributed through existing regional treatment centers and virtual clinics for an affordable and seamless patient experience.” 

How to engage: For more information about the THRIVE program, including solicitation details and to view the recording of the Proposers’ Day,  visit the THRIVE program page to view the recording

It’s GIVE-ing more treatments for patients. The GIVE program, or Genetic Medicines and Individualized Manufacturing for Everyone, aims to leverage cutting-edge production technologies to establish the U.S. as a frontrunner in advanced manufacturing methods for high-quality medicines.

Why it’s needed: Genetic medicines hold promise to make treatments in different formats. However, their development is often hindered by the high cost and complexity of manufacturing and quality testing, centralized facilities with specialized equipment needs, and ultracold shipping requirements.

• “These hurdles slow innovative research and prevent potentially lifesaving, affordable treatments and preventions from getting to the American people,” said Roos.

From the Program Manager: “Our vision is to rapidly produce multiple kinds of genetic medicines so that breakthrough treatments are accessible, affordable, and ready to dose within a week of diagnosis,” said GIVE Program Manager John Schiel, Ph.D. “Individualized domestic biomanufacturing will give the U.S. an advantage and ensure that researchers and patients alike have access to the latest therapeutic capabilities.”

How to engage: For more information about the GIVE program, including solicitation details and Proposers’ Day registration, visit the GIVE program page.

You received this email because you expressed an interest in ARPA-H. If you are not interested in receiving intermittent emails with ARPA-H news and events, please unsubscribe below.

Connect with us.

Interested in leading biomedical research that could change the world? Learn more at arpa-h.gov.

Note: HubSpot may collect geolocation data and time zone; IP address, time, and date of signup and opt-in confirmation.